First Participant Enrolled in Second Cohort of BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device